CB21 Pharma, the spin-off sister company to CBDepot, successfully extends EU GMP certification to broaden its cannabis-derived active pharmaceutical ingredients (API) portfolio.
CB21 Pharma, a leading Czech-based pharmaceutical company specializing in producing cannabinoid ingredients and medical devices, has successfully extended its EU Good Manufacturing Practice (GMP) certification under certificate # sukls105303/2023. This achievement allows CB21 Pharma, the spin-off sister company to pioneering CBDepot, to continue manufacturing Active Pharmaceutical Ingredients (APIs) such as Cannabidiol (CBD), from initial extraction to the production of full spectrum distilled and standardized extracts from medicinal cannabis, marketed as Cannabis Extractum Raffinatum and Cannabis Extractum Normatum.
CBDepot
-
SK
-
2017On CPHI since
-
2Certificates
-
25 - 49Employees
Other Content from CBDepot (1)
-
News CBDepot launches the sale of synthesized pharma-grade CBD
CBDepot group starts the marketing of synthesized pharma-grade CBD produced under the EU GMP umbrella of its sister company CB21 Pharma, s.r.o.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance